Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Low G, Huang G, Fu W, Moloo Z, Girgis S. Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol. 2016;8(5):484–500. doi:10.4329/wjr.v8.i5.48427247714
   PubMed Web of Science ®Google Scholar
• Shuch B, Amin A, Armstrong AJ, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. 2015;67(1):85–97. doi:10.1016/j.eururo.2014.04.02924857407
   PubMed Web of Science ®Google Scholar
• Goyal R, Gersbach E, Yang XJ, Rohan SM. Differential diagnosis of renal tumors with clear cytoplasm: clinical relevance of renal tumor subclassification in the era of targeted therapies and personalized medicine. Arch Pathol Lab Med. 2013;137(4):467–480. doi:10.5858/arpa.2012-0085-RA23544936
   PubMedGoogle Scholar
• Woldemeskel M. Renal cell carcinoma in humans and animals: a brief literature review. J Clin Exp Pathol. 2013;3(2). doi:10.4172/2161-0681.S7-001
   Google Scholar
• Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19(2):148–154.11354535
   PubMedGoogle Scholar
• Santoni M, Massari F, Di Nunno V, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212528.29899754
   PubMedGoogle Scholar
• Heng DY. The next 10 years: challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma. Can Urol Assoc J. 2016;10(11–12Suppl7):S256–S258.28096940
   PubMed Web of Science ®Google Scholar
• Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer. 2011;104(3):399–406.21285971
   PubMed Web of Science ®Google Scholar
• Cho DC. Therapeutic challenges in advanced renal cell carcinoma. Clin Pract (Lond). 2013;10(1):39–46. doi:10.2217/cpr.12.7723378893
   PubMedGoogle Scholar
• Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043. doi:10.18632/oncotarget.1672328410237
   PubMed Web of Science ®Google Scholar
• Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol. 2013;31(12):1592–1605. doi:10.1200/JCO.2011.37.641823509311
   PubMed Web of Science ®Google Scholar
• Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950–3957. doi:10.1200/JCO.2007.11.936218711184
   PubMed Web of Science ®Google Scholar
• Procopio G, Ratta R, de Braud F, Verzoni E. Combination therapies for patients with metastatic renal cell carcinoma. Lancet Oncol. 2018;19(3):281–283. doi:10.1016/S1470-2045(18)30092-529439858
   PubMedGoogle Scholar
• Buonerba C, Di Lorenzo G, Sonpavde G. Combination therapy for metastatic renal cell carcinoma. Ann Transl Med. 2016;4(5):100. doi:10.21037/atm.2016.04.0527047959
   PubMedGoogle Scholar
• Stephan S, Datta K, Wang E, et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res. 2004;10(20):6993–7000. doi:10.1158/1078-0432.CCR-04-080815501979
   PubMedGoogle Scholar
• Larkin J, Esser N, Calvo E, et al. Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. Anticancer Res. 2012;32(7):2399–2406.22753696
   PubMed Web of Science ®Google Scholar
• Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014;32(8):752–759. doi:10.1200/JCO.2013.50.530524297945
   PubMed Web of Science ®Google Scholar
• Ravaud A, Barrios CH, Alekseev B, et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26(7):1378–1384. doi:10.1093/annonc/mdv17025851632
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Manola JB, Pins M, et al. Best: a randomized phase ii study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma—a trial of the ECOG–ACRIN cancer research group (E2804). J Clin Oncol. 2015;33(21):2384–2391. doi:10.1200/JCO.2015.60.972726077237
   PubMed Web of Science ®Google Scholar
• Molina AM, Feldman DR, Voss MH, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2012;118(7):1868–1876. doi:10.1002/cncr.2642921898375
   PubMed Web of Science ®Google Scholar
• Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009;7(1):24–27. doi:10.3816/CGC.2009.n.00419213664
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482. doi:10.1016/S1470-2045(15)00290-926482279
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–2143. doi:10.1200/JCO.2009.26.556120368558
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Eng J Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Eng J Med. 2019;380(12):1103–1115. doi:10.1056/NEJMoa1816047
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Eng J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 2017;14(1):57–66. doi:10.1038/nrclinonc.2016.9627377132
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286. doi:10.3389/fphar.2015.0028626648870
   PubMed Web of Science ®Google Scholar
• Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep. 2002;22(2):129–150.12428898
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297–315.17717971
   PubMed Web of Science ®Google Scholar
• Jain A. Jain. Advances in Tumor Targeted Liposomes. Curr Mol Med. 2018;18(1):44–57. doi:10.2174/156652401866618041610152229663884
   PubMed Web of Science ®Google Scholar
• Dong M, Luo L, Ying X, et al. Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study. Onco Targets Ther. 2018;11:4247–4252. doi:10.2147/OTT.S16200330087568
   PubMed Web of Science ®Google Scholar
• Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond). 2013;8(9):1509–1528. doi:10.2217/nnm.13.11823914966
   PubMed Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(4):12. doi:10.3390/pharmaceutics9020012
   PubMed Web of Science ®Google Scholar
• Sinha S, Cao Y, Dutta S, Wang E, Mukhopadhyay D. VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma. J Cell Mol Med. 2010;14(3):647–658. doi:10.1111/j.1582-4934.2008.00578.x19017359
   PubMedGoogle Scholar
• Piguet A-C, Majumder S, Maheshwari U, et al. Everolimus is a potent inhibitor of activated hepatic stellate cell functionsin vitroandin vivo, while demonstrating anti-angiogenic activities. Clin Sci. 2014;126(11):775–791. doi:10.1042/CS2013008124283268
   PubMedGoogle Scholar
• Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15(5):1612–1622. doi:10.1158/1078-0432.CCR-08-205719223496
   PubMed Web of Science ®Google Scholar
• Jaafar-Maalej C, Diab R, Andrieu V, Elaissari A, Fessi H. Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation. J Liposome Res. 2009;20(3):228–243. doi:10.3109/08982100903347923
   Web of Science ®Google Scholar
• Bug D, Oswald E, Grote A, et al. Abstract 4815: humanized single mouse trial: a preclinical platform feasible for immune-oncology drug screening and translational biomarker development. Cancer Res. 2017;77(13 Supplement):4815.
   Google Scholar
• Gredy C, Schüler JB, Zanella N, Fiebig -H-H, Metz T. Abstract 2890: single mouse trials, a concept using patient-derived tumor xenografts for large scale in vivo screens. Cancer Res. 2015;75(15 Supplement):2890.
   Google Scholar
• Knudsen ES, Balaji U, Mannakee B, et al. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut. 2017.
   PubMed Web of Science ®Google Scholar
• Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014;344(1):1–12. doi:10.1016/j.canlet.2013.10.01024157811
   PubMed Web of Science ®Google Scholar
• Mignard C, Boisferon MHD, Bichat F, France D, Duchamp O. Abstract 2170: single mouse preclinical trial: a tool for translational research. Cancer Res. 2018;78(13 Supplement):2170.
   Web of Science ®Google Scholar
• Murphy B, Yin H, Maris JM, et al. Evaluation of alternative in vivo drug screening methodology: a single mouse analysis. Cancer Res. 2016;76(19):5798–5809. doi:10.1158/0008-5472.CAN-16-012227496711
   PubMed Web of Science ®Google Scholar
• Suarez C, Martinez M, Trilla E, et al. Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma. J Clin Oncol. 2016;34(2_suppl):551. doi:10.1200/jco.2016.34.2_suppl.551
   Web of Science ®Google Scholar
• Souza TGF, Ciminelli VST, Mohallem NDS. A comparison of TEM and DLS methods to characterize size distribution of ceramic nanoparticles. J Phys. 2016;733:012039.
   Google Scholar
• Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23(4):973–980. doi:10.1093/annonc/mdr36221890909
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997;80(7):1198–1220.9317170
   PubMed Web of Science ®Google Scholar
• Hanna SC, Heathcote SA, Kim WY. mTOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther. 2008;8(2):283–292. doi:10.1586/14737140.8.2.28318279068
   PubMed Web of Science ®Google Scholar
• Rosa R, Damiano V, Nappi L, et al. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. Br J Cancer. 2013;109(3):686–693. doi:10.1038/bjc.2013.36023839492
   PubMed Web of Science ®Google Scholar
• Wu SW, Chen PN, Lin CY, Hsieh YS, Chang HR. Everolimus suppresses invasion and migration of renal cell carcinoma by inhibiting FAK activity and reversing epithelial to mesenchymal transition in vitro and in vivo. Environ Toxicol. 2017;32(7):1888–1898. doi:10.1002/tox.2241128258630
   PubMedGoogle Scholar
• Alshaker H, Wang Q, Böhler T, et al. Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1. Sci Rep. 2017;7(1):3493. doi:10.1038/s41598-017-03728-328615679
   PubMedGoogle Scholar
• Buti S, Leonetti A, Dallatomasina A, Bersanelli M. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid. 2016;11:23–36. doi:10.2147/CE.S9868727621699
   PubMed Web of Science ®Google Scholar
• Houghton PJ. Everolimus. Clin Cancer Res. 2010;16(5):1368–1372. doi:10.1158/1078-0432.CCR-09-131420179227
   PubMed Web of Science ®Google Scholar
• Moudi M, Go R, Yien CY, Nazre M. Vinca alkaloids. Int J Prev Med. 2013;4(11):1231–1235.24404355
   PubMedGoogle Scholar
• El-Galley R, Keane TE, Sun C. Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft. Urol Oncol. 2003;21(1):49–57.12684128
   PubMed Web of Science ®Google Scholar
• Goldstein D, Ackland SP, Bell DR, et al. Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Invest New Drugs. 2006;24(5):429–434.16528478
   PubMed Web of Science ®Google Scholar
• Gregory RK, Smith IE. Vinorelbine–a clinical review. Br J Cancer. 2000;82(12):1907–1913.10864196
   PubMed Web of Science ®Google Scholar
• Stravodimou A, Zaman K, Voutsadakis IA. Vinorelbine with or without trastuzumab in metastatic breast cancer: a retrospective single institution series. ISRN Oncol. 2014;2014:289836.25006504
   PubMedGoogle Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–951.26348965
   PubMed Web of Science ®Google Scholar
• Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems - a review (part 1). Trop J Pharm Res. 2013;12(2):255–264.
   Web of Science ®Google Scholar
• O’Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs. 2011;22(1):58–78.20890178
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Inaba M, Tashiro T, et al. Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice. Anticancer Drugs. 1994;5(6):634–640.7888700
   PubMed Web of Science ®Google Scholar